Literature DB >> 28441175

Acceptability and use of a dapivirine vaginal ring in a phase III trial.

Elizabeth T Montgomery1, Ariane van der Straten, Miria Chitukuta, Krishnaveni Reddy, Kubashni Woeber, Millicent Atujuna, Linda-Gail Bekker, Juliane Etima, Teopista Nakyanzi, Ashley J Mayo, Ariana Katz, Nicole Laborde, Cynthia I Grossman, Lydia Soto-Torres, Thesla Palanee-Phillips, Jared M Baeten.   

Abstract

BACKGROUND: The MTN-020/ASPIRE trial evaluated the safety and effectiveness of the dapivirine vaginal ring for prevention of HIV-1 infection among African women. A nested qualitative component was conducted at six of 15 study sites in Uganda, Malawi, Zimbabwe and South Africa to evaluate acceptability of and adherence to the ring.
METHOD: Qualitative study participants (n = 214) were interviewed with one of three modalities: single in-depth interview, up to three serial interviews or an exit Focus Group Discussion. Using semistructured guides administered in local languages, 280 interviews were audio-recorded, transcribed, translated, coded and analyzed.
RESULTS: We identified three key findings: first, despite initial fears about the ring's appearance and potential side effects, participants grew to like it and developed a sense of ownership of the ring once they had used it. Second, uptake and sustained adherence challenges were generally overcome with staff and peer support. Participants developed gradual familiarity with ring use through trial progression, and most reported that it was easy to use and integrate into their lives. Using the ring in ASPIRE was akin to joining a team and contributing to a broader, communal good. Third, the actual or perceived dynamics of participants' male partner relationship(s) were the most consistently described influence (which ranged from positive to negative) on participants' acceptability and use of the ring.
CONCLUSION: It is critical that demonstration projects address challenges during the early adoption stages of ring diffusion to help achieve its potential public health impact as an effective, long-acting, female-initiated HIV prevention option addressing women's disproportionate HIV burden.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28441175      PMCID: PMC5557083          DOI: 10.1097/QAD.0000000000001452

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  32 in total

1.  High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women.

Authors:  A van der Straten; E T Montgomery; H Cheng; L Wegner; G Masenga; C von Mollendorf; L Bekker; S Ganesh; K Young; J Romano; A Nel; C Woodsong
Journal:  AIDS Behav       Date:  2012-10

2.  Adolescent experiences with the vaginal ring.

Authors:  Laura B Epstein; Karen Sokal-Gutierrez; Susan L Ivey; Tina Raine; Colette Auerswald
Journal:  J Adolesc Health       Date:  2008-03-10       Impact factor: 5.012

3.  Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.

Authors:  Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden
Journal:  Lancet Infect Dis       Date:  2014-07-22       Impact factor: 25.071

4.  Re-framing microbicide acceptability: findings from the MDP301 trial.

Authors:  Catherine M Montgomery; Mitzy Gafos; Shelley Lees; Neetha S Morar; Oliver Mweemba; Agnes Ssali; Jonathan Stadler; Robert Pool
Journal:  Cult Health Sex       Date:  2010-08

5.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

Review 6.  Acceptability in microbicide and PrEP trials: current status and a reconceptualization.

Authors:  Barbara S Mensch; Ariane van der Straten; Lauren L Katzen
Journal:  Curr Opin HIV AIDS       Date:  2012-11       Impact factor: 4.283

7.  Disclosure of pharmacokinetic drug results to understand nonadherence.

Authors:  Ariane van der Straten; Elizabeth T Montgomery; Petina Musara; Juliane Etima; Sarita Naidoo; Nicole Laborde; Miriam Hartmann; Lisa Levy; Thola Bennie; Helen Cheng; Jeanna Piper; Cynthia I Grossman; Jeanne Marrazzo; Barbara Mensch
Journal:  AIDS       Date:  2015-10-23       Impact factor: 4.177

8.  Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention.

Authors:  Thesla Palanee-Phillips; Katie Schwartz; Elizabeth R Brown; Vaneshree Govender; Nyaradzo Mgodi; Flavia Matovu Kiweewa; Gonasagrie Nair; Felix Mhlanga; Samantha Siva; Linda-Gail Bekker; Nitesha Jeenarain; Zakir Gaffoor; Francis Martinson; Bonus Makanani; Sarita Naidoo; Arendevi Pather; Jessica Phillip; Marla J Husnik; Ariane van der Straten; Lydia Soto-Torres; Jared Baeten
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

9.  Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa.

Authors:  Annalene Nel; Linda-Gail Bekker; Elizabeth Bukusi; Elizabeth Hellstrӧm; Philip Kotze; Cheryl Louw; Francis Martinson; Gileard Masenga; Elizabeth Montgomery; Nelisiwe Ndaba; Ariane van der Straten; Neliëtte van Niekerk; Cynthia Woodsong
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

10.  Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

Authors:  Sheena McCormack; David T Dunn; Monica Desai; David I Dolling; Mitzy Gafos; Richard Gilson; Ann K Sullivan; Amanda Clarke; Iain Reeves; Gabriel Schembri; Nicola Mackie; Christine Bowman; Charles J Lacey; Vanessa Apea; Michael Brady; Julie Fox; Stephen Taylor; Simone Antonucci; Saye H Khoo; James Rooney; Anthony Nardone; Martin Fisher; Alan McOwan; Andrew N Phillips; Anne M Johnson; Brian Gazzard; Owen N Gill
Journal:  Lancet       Date:  2015-09-09       Impact factor: 79.321

View more
  55 in total

1.  Reasons for nonadherence to the dapivirine vaginal ring: narrative explanations of objective drug-level results.

Authors:  Elizabeth T Montgomery; Jonathan Stadler; Sarita Naidoo; Ariana W K Katz; Nicole Laborde; Morgan Garcia; Krishnaveni Reddy; Leila E Mansoor; Juliane Etima; Chifundo Zimba; Miria Chitukuta; Lydia Soto-Torres
Journal:  AIDS       Date:  2018-07-17       Impact factor: 4.177

Review 2.  Generating CHARISMA: Development of an Intervention to Help Women Build Agency and Safety in Their Relationships While Using PrEP for HIV Prevention.

Authors:  Miriam Hartmann; Michele Lanham; Thesla Palanee-Phillips; Florence Mathebula; Elizabeth E Tolley; Dean Peacock; Laura Pascoe; Seth Zissette; Sarah T Roberts; Danielle Wagner; Ellen Wilson; Asha Ayub; Rose Wilcher; Elizabeth T Montgomery
Journal:  AIDS Educ Prev       Date:  2019-10

3.  Relationship Type and Use of the Vaginal Ring for HIV-1 Prevention in the MTN 020/ASPIRE Trial.

Authors:  E Pleasants; T Tauya; K Reddy; B G Mirembe; K Woeber; T Palanee-Phillips; C Zimba; M Atujuna; E T Montgomery
Journal:  AIDS Behav       Date:  2020-03

4.  Synthesis of a long acting nanoformulated emtricitabine ProTide.

Authors:  Dhruvkumar Soni; Aditya N Bade; Nagsen Gautam; Jonathan Herskovitz; Ibrahim M Ibrahim; Nathan Smith; Melinda S Wojtkiewicz; Bhagya Laxmi Dyavar Shetty; Yazen Alnouti; JoEllyn McMillan; Howard E Gendelman; Benson J Edagwa
Journal:  Biomaterials       Date:  2019-08-20       Impact factor: 12.479

5.  Design and Characterization of a Novel Series of Geometrically Complex Intravaginal Rings with Digital Light Synthesis.

Authors:  Rima Janusziewicz; Sue J Mecham; Kevin R Olson; S Rahima Benhabbour
Journal:  Adv Mater Technol       Date:  2020-06-23

6.  First Impressions Matter: How Initial Worries Influence Adherence to the Dapivirine Vaginal Ring.

Authors:  Ariane van der Straten; Erica N Browne; Mary Kate Shapley-Quinn; Elizabeth R Brown; Krishnaveni Reddy; Rachel Scheckter; Lydia Soto-Torres; Thesla Palanee-Phillips; Jared M Baeten; Barbara Mensch
Journal:  J Acquir Immune Defic Syndr       Date:  2019-07-01       Impact factor: 3.731

7.  Hygiene, Blood Flow, and Vaginal Overload: Why Women Removed an HIV Prevention Vaginal Ring During Menstruation in Malawi, South Africa, Uganda and Zimbabwe.

Authors:  Zoe Duby; Ariana W K Katz; Erica N Browne; Prisca Mutero; Juliane Etima; Chifundo Colleta Zimba; Kubashni Woeber; Millicent Atujuna; Krishnaveni Reddy; Ariane van der Straten
Journal:  AIDS Behav       Date:  2020-02

8.  "The state of mind tells me it's dirty": menstrual shame amongst women using a vaginal ring in Sub Saharan Africa.

Authors:  Zoe Duby; Ariana Katz; Petina Musara; Josephine Nabukeera; Chifundo Colleta Zimba; Kubashni Woeber; Thesla Palanee-Phillips; Ariane van der Straten
Journal:  Women Health       Date:  2019-05-01

9.  Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings.

Authors:  Craig J Hoesley; Beatrice A Chen; Peter L Anderson; Charlene S Dezzutti; Julie Strizki; Carol Sprinkle; Faye Heard; Jose Bauermeister; Wayne Hall; Cindy Jacobson; Jennifer Berthiaume; Ashley Mayo; Holly Gundacker; Nicola Richardson-Harman; Jeanna Piper
Journal:  Clin Infect Dis       Date:  2019-03-19       Impact factor: 9.079

10.  Behavioral and social science research to support development of educational materials for clinical trials of broadly neutralizing antibodies for HIV treatment and prevention.

Authors:  Pablo K Valente; Yumeng Wu; Yehuda Z Cohen; Marina Caskey; Kathrine Meyers
Journal:  Clin Trials       Date:  2020-08-24       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.